S P E C I A L I N T E R V I E W
introduced regulatory reforms relating to conduct clinical trials . In 2020 , India accounted for 8.3 % of global clinical trial activity , a notable increase from the ten-year average of 6.2 %. This growth reflects the impact of regulatory reforms and increased investment in the clinical research sector .
How does Veeda Clinical Research position itself in a rapidly evolving clinical research landscape and navigate the complex regulatory environment in India ?
Veeda Clinical Research has strategically positioned itself as a leading player in the clinical research landscape by focusing on several key areas . One of these is strategic expansion and capabilities . The company has added capabilities in late-stage clinical trials with the acquisition of European CRO and can now participate in global clinical trials . Recognizing the need for offering integrated services , Veeda is now also offering preclinical services . Recently Veeda launched a biopharma
division which focuses on supporting non-clinical services for development of biologics including cell line development , analytical characterization , process characterization , bioanalytical sample testing , and comparability assessments for biosimilars .
Veeda is now partnering to dramatically change the speed of patient recruitment in clinical trials . Through exclusive access to real world data , patient matching solutions bring Veeda much closer to the right physicians and patients who are eligible for enrolment in clinical trials .
Veeda has aligned itself with international regulatory standards and best practices . We have a strong focus on quality assurance and regulatory compliance , which enhances our credibility . The evolving regulatory landscape in India , including the introduction of the New Drugs and Clinical Trial Rules in 2019 , has made the country a more attractive destination for clinical trials . Veeda has adapted to these changes by ensuring compliance with the new regulations .
“ The acquisitions of Bioneeds in 2021 and Heads in 2024 have significantly bolstered Veeda Clinical Research ’ s capabilities and market position .”
26
BioVoiceNews | October 2024